Lavengratinib

Small molecule

Also known as ABSK061

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Achondroplasia · Phase 1/2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Non-Small Cell Lung Cancer
Phase 1/2 (1)
Achondroplasia
Phase 1 (2)
Other / comorbidity
NCT07007546 · Abbisko Therapeutics Co, Ltd
2025-05-17 – 2026-04-14 · Healthy
What this study did
NCT05244551 · Abbisko Therapeutics Co, Ltd
2022-06-30 – 2025-04-30 · Solid Tumor
What this study did

Competitive landscape

This drug's own stage for Achondroplasia: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lavengratinib: this drugPhase 1/2Small moleculeFGFR2 / FGFR3not yet gradedNo reviewed efficacy summary in this indication
Vosoritide (VOXZOGO)ApprovedPeptideNatriuretic peptide receptor B (NPR-B)Reliable signal
NCT03197766: Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 (At Baseline and Week 52): BMN 111 - 15 μg/kg 1.71 cm/year (95% CI 1.4 to 2.01) | Placebo 0.13 cm/year (95% CI -0.18 to 0.45)
BMN 333Phase 2/3PeptideC-type natriuretic peptide (CNP) pathwaynot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lavengratinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 1/2AchondroplasiaNot yet recruiting
Est. primary completion 2028-12-15 · NCT07297875 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-11-30 · NCT06632262 · CT.gov ↗
What to watch

See the full readout calendar ↗